Citations

Mayo Clinic

Showing 10 of 108572 citations.

A Randomized Phase IIb Trial of myo -Inositol in Smokers with Bronchial Dysplasia
Lam, Stephen , Mandrekar, Sumithra J. , Gesthalter, Yaron , Ziegler, Katie L. Allen, Seisler, Drew K., Midthun, David E. , Mao, Jenny T., Aubry, Marie Christine, McWilliams, Annette , Shaipanich, Tawimas , Liu, Gang , Johnson, Evan, Bild, Andrea H. , Lenburg, Marc E. , Mayo, John R. , Yi, Joanne, Tazelaar, Henry D. , Harmsen, William S. , Smith, Judith, Beane, Jennifer , Szabó, Éva , Johnson, W. Evan , Allen Ziegler, Katie L, Yi, Joanne Eunhee, Tazelaar, Henry, Limburg, Paul J. , Sin, Don D , Johnson, Evan, Ionescu, Diana N. , Tazelaar, Henry D. , Spira, Avrum , Szabo, Eva

Cancer Prevention Research | September 22, 2016 | Volume: 9 | Issue: 12 | Pages: 906-914

10.1158/1940-6207.capr-15-0254 | PMID 27658890 Get It

Abstract Previous preclinical studies and a phase I clinical trial suggested that myo-inositol may be a safe and effective lung cancer chemopreventive agent. We conducted a randomized, double blind, placebo-controlled phase IIb study to determine the chemopreventive effects of myo-inositol in smokers with bronchial dysplasia. Smokers with ≥1 site of dysplasia identified by autofluorescence bronchoscopy-directed biopsy were randomly assigned to receive oral placebo or myo-inositol, 9 g once a day for 2 weeks, and then twice a day for 6 months. The primary endpoint was change in dysplasia rate after 6 months of intervention on a per-participant basis. Other trial endpoints reported herein include Ki-67 labeling index, blood and bronchoalveolar lavage fluid (BAL) levels of proinflammatory, oxidant/antioxidant biomarkers, and an airway epithelial gene expression signature for PI3K activity. Seventy-four (n = 38 myo-inositol and n = 36 placebo) participants with a baseline and 6-month bronchoscopy were included in all efficacy analyses. The complete response and the progressive disease rates were 26.3% versus 13.9% and 47.4% versus 33.3%, respectively, in the myo-inositol and placebo arms (P = 0.76). Compared with placebo, myo-inositol intervention significantly reduced IL6 levels in BAL over 6 months (P = 0.03). Among those with a complete response in the myo-inositol arm, there was a significant decrease in a gene expression signature reflective of PI3K activation within the cytologically normal bronchial airway epithelium (P = 0.002). The heterogeneous response to myo-inositol suggests a targeted therapy approach based on molecular alterations is needed in future clinical trials to determine the efficacy of myo-inositol as a chemopreventive agent. Cancer Prev Res; 9(12); 906–14. ©2016 AACR.
Liver transplantation after share 35: Impact on pretransplant and posttransplant costs and mortality
Nicolas, Clara T., Nyberg, Scott L. , Watt, Kymberly D. , Chen, Harvey S., Hathcock, Matthew , Kremers, Walter K. , Watt, Kymberly, Hathcock, Matthew A, Heimbach, Julie K. , Kremers, Walter K

Liver Transplantation | September 22, 2016 | Volume: 23 | Issue: 1 | Pages: 11-18

10.1002/lt.24641 | PMID 27658200 Get It

Share 35 was implemented in 2013 to direct livers to the most urgent candidates by prioritizing Model for End‐Stage Liver Disease (MELD) ≥ 35 patients. We aim to evaluate this policy's impact on costs and mortality. Our study includes 834 wait‐listed patients and 338 patients who received deceased donor, solitary liver transplants at Mayo Clinic between January 2010 and December 2014. Of these patients, 101 (30%) underwent transplantation after Share 35. After Share 35, 29 (28.7%) MELD ≥ 35 patients received transplants, as opposed to 46 (19.4%) in the pre–Share 35 era (P = 0.06). No significant difference in 90‐day wait‐list mortality (P = 0.29) nor 365‐day posttransplant mortality (P = 0.68) was found between patients transplanted before or after Share 35. Mean costs were $3,049 (P = 0.30), $5226 (P = 0.18), and $10,826 (P = 0.03) lower post‐Share 35 for the 30‐, 90‐, and 365‐day pretransplant periods, and mean costs were $5010 (P = 0.41) and $5859 (P = 0.57) higher, and $9145 (P = 0.54) lower post‐Share 35 for the 30‐, 90‐, and 365‐day posttransplant periods. In conclusion, the added cost of transplanting more MELD ≥ 35 patients may be offset by pretransplant care cost reduction. Despite shifting organs to critically ill patients, Share 35 has not impacted mortality significantly. Liver Transplantation 23:11–18 2017 AASLD.
HDL Cholesterol Story Is Dead: Long Live HDL!
Simha, Vinaya , Kudva, Yogish C.

Diabetes | September 22, 2016 | Volume: 65 | Issue: 10 | Pages: 2826-2828

10.2337/dbi16-0039 | PMID 27659225 Get It

Eulogy for the Metabolic Clinical Investigator?
Jensen, Michael D. , Vella, Adrian , Nair, K. Sreekumaran

Diabetes | September 22, 2016 | Volume: 65 | Issue: 10 | Pages: 2821-2823

10.2337/db16-0923 | PMID 27659223 Get It

Automated Compression Device for Viscoelasticity Imaging
Nabavizadeh, Alireza , Kinnick, Randall R., Bayat, Mahdi , Amador, Carolina , Fatemi, Mostafa , Urban, Matthew W. , Alizad, Azra , Fatemi, Mostafa

IEEE Transactions on Biomedical Engineering | September 22, 2016 | Volume: 64 | Issue: 7 | Pages: 1535-1546

10.1109/tbme.2016.2612541 | PMID 28113299 Get It

Addressing obesity in homeless children
Levine, James A. , McCrady-Spitzer, Shelly , Batko, S. M., McCrady-Spitzer, Shelly K, Batko, Samantha

Science | September 22, 2016 | Volume: 353 | Issue: 6306 | Pages: 1374-1375

10.1126/science.aaj1468 | PMID 27708029 Get It

MRI-Guided Prostate Interventions
Walser, Eric , Sze, Thaddeus F.-C., Ross, Jason R, Karamanian, Ara , Woodrum, David A.

American Journal of Roentgenology | September 22, 2016 | Volume: 207 | Issue: 4 | Pages: 755-763

10.2214/ajr.16.16663 | PMID 30240324 Get It

Genetic variants in CETP increase risk of intracerebral hemorrhage
Anderson, Christopher D. , Falcone, Guido J. , Phuah, Chia‐Ling , Radmanesh, Farid , Brouwers, H. Bart , Battey, Thomas W.K., Biffi, Alessandro , Liu, Dajiang J. , Viswanathan, Anand , Greenberg, Steven M. , Brown, Devin L. , Worrall, Bradford B. , Silliman, Scott, Tirschwell, David , Flaherty, Matthew L. , Kraft, Peter , Jagiełła, Jeremiasz , Schmidt, Helena , Hansen, Björn M. , Jiménez-Conde, Jordi , Giralt‐Steinhauer, Eva , Elosúa, Roberto , Cuadrado‐Godia, Elisa , Soriano‐Tárraga, Carolina , Nieuwenhuizen, Koen M. van , Klijn, Catharina J.M. , Rannikmäe, Kristiina , Samarasekera, Neshika , Salman, Rustam Al‐Shahi , Sudlow, Catherine L., Deary, Ian J. , Morotti, Andrea , Pezzini, Alessandro , Pera, Joanna , Urbanik, Andrzej, Pichler, Alexander , Montaner, Joan , Fernández‐Cadenas, Israel , Delgado, Pilar , Słowik, Agnieszka , Schmidt, Reinhold, Kidwell, Chelsea S., Kittner, Steven J. , Waddy, Salina P., Langefeld, Carl D. , Kathiresan, Sekar , Woo, Daniel , Sudlow, Cathie , Lee, Chaeyoung , Meschia, James F , van Nieuwenhuizen, Koen M , Peloso, Gina M. , Ayres, Alison M. , Goldstein, Joshua Norkin , Selim, Magdy H. , Meschia, James F. , Enzinger, Christian , Norrving, Bo , Roquer, Jaume , Lindgren, Arne G. , Abecasis, Gonçalo R. , Willer, Cristen J , Rosand, Jonathan M. , Kraft, Peter , Montaner, Joan , Pezzini, Alessandro , Al-Shahi Salman, Rustam

Annals of Neurology | September 22, 2016 | Volume: 80 | Issue: 5 | Pages: 730-740

10.1002/ana.24780 | PMID 27717122 Get It

ObjectiveIn observational epidemiologic studies, higher plasma high‐density lipoprotein cholesterol (HDL‐C) has been associated with increased risk of intracerebral hemorrhage (ICH). DNA sequence variants that decrease cholesteryl ester transfer protein (CETP) gene activity increase plasma HDL‐C; as such, medicines that inhibit CETP and raise HDL‐C are in clinical development. Here, we test the hypothesis that CETP DNA sequence variants associated with higher HDL‐C also increase risk for ICH.MethodsWe performed 2 candidate‐gene analyses of CETP. First, we tested individual CETP variants in a discovery cohort of 1,149 ICH cases and 1,238 controls from 3 studies, followed by replication in 1,625 cases and 1,845 controls from 5 studies. Second, we constructed a genetic risk score comprised of 7 independent variants at the CETP locus and tested this score for association with HDL‐C as well as ICH risk.ResultsTwelve variants within CETP demonstrated nominal association with ICH, with the strongest association at the rs173539 locus (odds ratio [OR] = 1.25, standard error [SE] = 0.06, p = 6.0 × 10−4) with no heterogeneity across studies (I2 = 0%). This association was replicated in patients of European ancestry (p = 0.03). A genetic score of CETP variants found to increase HDL‐C by ∼2.85mg/dl in the Global Lipids Genetics Consortium was strongly associated with ICH risk (OR = 1.86, SE = 0.13, p = 1.39 × 10−6).InterpretationGenetic variants in CETP associated with increased HDL‐C raise the risk of ICH. Given ongoing therapeutic development in CETP inhibition and other HDL‐raising strategies, further exploration of potential adverse cerebrovascular outcomes may be warranted. Ann Neurol 2016;80:730–740
Weighing the risks and benefits ofPneumocystispneumonia prophylaxis in iatrogenically immunosuppressed dermatology patients
Lehman, Julia S. , Santiago, Tania M. González, Wetter, David A. , Kalaaji, Amer N., Gonzalez Santiago, Tania M, Limper, Andrew H. , Lehman, Julia S

International Journal of Dermatology | September 22, 2016 | Volume: 56 | Issue: 1 | Pages: e5-e6

10.1111/ijd.13396 | PMID 27653234 Get It

Involvement of the nucleus accumbens and dopamine system in chronic pain
Benarroch, Eduardo E.

Neurology | September 22, 2016 | Volume: 87 | Issue: 16 | Pages: 1720-1726

10.1212/wnl.0000000000003243 | PMID 27655737 Get It